gabexate has been researched along with Cystic Fibrosis of Pancreas in 1 studies
Gabexate: A serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotrypsin and aprotinin.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF)." | 9.17 | Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. ( Abbi, S; Clancy, JP; Danahay, H; Hathorne, H; Lock, R; Reeves, G; Renard, D; Rowe, SM; Solomon, GM; Waltz, DA; Zhou, P, 2013) |
| " Its direct inhibition by camostat represents a potential approach to inhibiting sodium transport in cystic fibrosis (CF)." | 5.17 | Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis. ( Abbi, S; Clancy, JP; Danahay, H; Hathorne, H; Lock, R; Reeves, G; Renard, D; Rowe, SM; Solomon, GM; Waltz, DA; Zhou, P, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rowe, SM | 1 |
| Reeves, G | 1 |
| Hathorne, H | 1 |
| Solomon, GM | 1 |
| Abbi, S | 1 |
| Renard, D | 1 |
| Lock, R | 1 |
| Zhou, P | 1 |
| Danahay, H | 1 |
| Clancy, JP | 1 |
| Waltz, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients[NCT04530617] | Phase 2 | 246 participants (Actual) | Interventional | 2020-10-05 | Terminated (stopped due to Results from the interim analysis) | ||
| A Two-part, Randomized, Double-blind, Placebo-controlled, Ascending Single-dose, Adaptive Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of QAU145 Administered Via a Nasal Spray Pump to Patients With Cystic Fibrosis[NCT00506792] | Phase 2 | 9 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gabexate and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |
Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis.
Topics: Administration, Intranasal; Adult; Biological Transport; Chlorides; Cross-Over Studies; Cystic Fibro | 2013 |